Stockreport

Forty Seven Validates CD47 With 'Don't Eat Me' Tech, Pivotal Studies To Be Initiated In 2020 [Seeking Alpha]

FORTY SEVEN  (FTSV) 
Last forty seven earnings: 11/12 07:01 am Check Earnings Report
PDF Summary Forty Seven intends to initiate the pivotal phase 3 ENHANCE study exploring magrolimab in combination with azacitidine versus azacitidine alone by Q2 of 2020. Ad [Read more]